Medical writing funded by Alcon Research, Ltd., was provided by Magdalene Chu of DJE Science. Anthony Realini of Hypotony Holdings, LLC, provided writing assistance (funded by Alcon Research, Ltd.) on an early draft.
Supported by Alcon Research, Ltd., research funding from the National Institutes of Health and the Virginia Eye Foundation (JDS), investigator-initiated grants from the National Eye Institute and the Food and Drug Administration (JHK), and research funding from Research to Prevent Blindness and the Mackall Foundation (JHK).
Disclosure: J.D. Sheppard, 1-800-Doctors (I), Abbott (C), Abbvie (C), Alcon (C), Alimera (C), Allergan (C), Bausch & Lomb (C), EyeGate (I, C), EyeRx (I), Gerson Lehrman (C), Inspire (C), Ista (C), Lux Biosciences (C), Merck (C), Mimetogen (C), OcuCure (I), Omeros (C), Santen (C), SarCode (C), Science Based Health (C), TearLab (I, C), Vistakon (C); M.M. Toyos, Allergan (C, R), Alcon (F, C), Toyos Clinic (S), Ista (F, C), Bausch & Lomb (F, C), Inspire (C), Pfizer (F), Shire (F), iTherapeutix (F); J.H. Kempen, Alcon (C), Allergan (C), Clearside (C), Can-Fite (C), EyeGate (F), Lux Biosciences (C), Sanofi Pasteur (C), Xoma (F, C); P. Kaur, Alcon (F, E); C.S. Foster, Abbott (F, C), Alcon (F, C, R), Allergan (F, C, R), Bausch & Lomb (R), Eyegate (F, I), Inspire (R), Ista (C, R), Lux Biosciences (F, C, R), Novartis (C, F)